GenMark Diagnostics’ outcome of analysis shows that its ePlex Respiratory Pathogen Panel 2 is predicted to identify all known SARS-CoV-2 Variants.
FREMONT, CA: GenMark Diagnostics, a leading provider of automated, multiplex molecular diagnostic testing systems, announces that its ePlex Respiratory Pathogen Panel 2 (RP2) is predicted to identify known SARS-CoV-2 variants presently in circulation.
As the COVID-19 pandemic continues to emerge, GenMark is routinely monitoring public databases for new SARS-CoV-2 strains and variants and running bioinformatic analyses to decide if the mutations present in the viral genome would affect the detection of variants on the ePlex RP2 Panel. The recently identified SARS-CoV-2 variant includes several mutations, with the majority happening in the spike protein, S gene region, and mutations found in the nucleoprotein region, or N gene. The ePlex RP2 Panel targets two unique places of the N gene; the presently identified N gene mutations for the above variants are found outside of the sequence region targeted by the SARS-CoV-2 assays on the ePlex RP2 Panel GenMark will continue to update the list of variants identified by the ePlex RP2 Panel.
The ePlex RP2 Panel offers results for more than 20 viruses and bacteria that cause common and often serious respiratory infections, comprising COVID-19, flu, pneumonia, bronchitis, and the common cold. With less than one minute of laboratory time and a total run time of fewer than two hours, the ePlex RP2 Panel is seamless to use, quick and can be run in a wide array of hospital and reference lab settings.
The U.S. ranks 43rd in the world in the sequencing of SARS-CoV-2 viral samples. To address this hurdle, the Tracking COVID Variants Act was introduced to significantly boost funding and support for innovative molecular detection technologies at the Centers for Disease Control and Prevention (CDC) to offer robust genetic surveillance and sequencing tasks for SARS-CoV-2 variants. GenMark joined with many American Society Society members for Microbiology Corporate Council to help this important effort to accelerate the nation’s genomic surveillance and sequencing potential by signing a stakeholder letter and expressing help for the bill. Specifically, the proposed bill authorizes up to $1.75 billion in emergency supplemental funding for the CDC.